Currently out of the existing stock ratings of Balaji Prasad, 23 are a SELL (11.27%), 17 are a HOLD (8.33%), 164 are a BUY (80.39%).

Balaji Prasad

Work Performance Price Targets & Ratings Chart

Analyst Balaji Prasad, currently employed at BARCLAYS, carries an average stock price target met ratio of 55.34% that have a potential upside of 23.8% achieved within 274 days.

Balaji Prasad’s has documented 415 price targets and ratings displayed on 25 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on EOLS, Evolus at 05-Mar-2025.

Wall Street Analyst Balaji Prasad

Analyst best performing recommendations are on MNK (MALLINCKRODT PLC).
The best stock recommendation documented was for LGND (LIGAND PHARMACEUTICALS) at 2/4/2021. The price target of $123.52 was fulfilled within 1 day with a profit of $11.16 (9.93%) receiving and performance score of 99.32.

Average potential price target upside

of $92.82 (19.51%) on IDXX (IDEXX LABORATORIES).
of $45.12 (36.19%) on JAZZ (JAZZ PHARMACEUTICALS PLC).
of $28.82 (38.91%) on LGND (LIGAND PHARMACEUTICALS).

BHC Bausch Health Companies CHRS Coherus BioSciences ELAN Elanco Animal Health ENDP Endo International PLC EOLS Evolus IDXX IDEXX Laboratories JAZZ Jazz Pharmaceuticals PLC LGND Ligand Pharmaceuticals PAHC Phibro Animal Health PCRX Pacira Pharmaceuticals RDY Dr. Reddy’s Laboratories Ltd ADR RVNC Revance The TEVA Teva Pharma Industries Ltd ADR ZTS Zoetis VTRS Viatris AMAG AMAG Pharmaceuticals AMRX Amneal Pharmaceuticals, Common Stock CVET Covetrus MNK Mallinckrodt plc PYPD PolyPid RVLP RVL Pharmaceuticals PLC ALVO Alvotech TARS Tarsus Pharmaceuticals OGN Organon KIN Kindred Biosciences

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Glen Santangelo (BARCLAYS)